Changes in Prostate-Specific Antigen and Prostatic Acid Phosphatase Concentration following Prostatic Examination in Benign Prostatic Hypertrophy and Prostate Cancer Patients

1992 ◽  
Vol 21 (1) ◽  
pp. 83-86 ◽  
Author(s):  
I. Romics ◽  
L. Galamb
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hypertrophy

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

1989 ◽  
Vol 4 (2) ◽  
pp. 87-94 ◽  
Author(s):  
J. Morote Robles ◽  
A. Ruibal Morell ◽  
J.A. De Torres Mateos ◽  
A. Soler Roselló
Keyword(s):  
Acid Phosphatase ◽  
False Positive ◽  
Normal Limit ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Acid Phosphatase ◽  
Serum Levels ◽  
Prostatic Hypertrophy ◽  
Prostatic Specific Antigen ◽  
Positive Results

We assayed prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) serum levels in 1383 patients using a double antibody radioimmunoassay (RIA) I125. Establishing the upper normal limit in 10 ng/ml PSA and 2.5 ng/ml for PAP, the false positive results were only 1.9 and 5.1 percent in men with non-prostatic benign or malignant pathology and respectively 0 and 2.2 percent in women. We detected false positive levels for these two tumoral markers in 3.5 and 4.7 percent of patients with non-complicated benign prostatic hypertrophy, 64.8 and 19.2 percent in complicated benign prostatic hypertrophy, 24 and 16 percent in acute prostatitis and 3.3 percent in chronic prostatitis. The sensitivity in patients with prostate cancer was 87.2 percent for PSA and 64.1 percent for PAP, and there was a better correlation with PSA than PAP for tumoral spread and histological grading. Finally, clinical efficacy was higher with PSA and was no better when both markers were assayed.

Prostate-Specific Antigen in Prostate Cancer

1986 ◽  
Vol 1 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Manabu Kuriyama
Keyword(s):  
Prostate Cancer ◽  
Tumor Marker ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
False Positive Rate ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
High Sensitivity ◽  
Positive Rate ◽  
Normal Controls

Prostate-specific antigen (PA) has been evaluated clinically as a tumor marker of prostate cancer with the use of enzyme immunoassay (EIA). For serodetection of prostate cancer, PA was assayed in a total of 1,109 sera. From mean ± 3 S.D. of normal controls, upper cut-off values in males were decided as 2.5 and 1.2 ng/ml in Americans and Japanese, respectively. Serum PA values in prostate cancer patients were positive in 78% of Americans and 62% of Japanese. However, in benign prostatic hypertrophy (BPH) cases, a high false positive rate of 41% was observed in Americans. Simultaneous assays of serum PA and PAP showed high sensitivity and specificity in the detection of prostate cancer. This antigen could be used, as well as PAP, for monitoring prostate cancer patients. Furthermore, serum PA levels prior to treatment may express to some degree the malignant potential of the cancer. These results suggest that PA may be useful as a tumor marker of prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document